Analyst Price Targets — TRAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 10, 2026 10:04 am | Emily Bodnar | H.C. Wainwright | $44.00 | $32.40 | TheFly | First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright |
| June 8, 2026 8:58 am | Derek Archila | Wells Fargo | $30.00 | $16.60 | TheFly | First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo |
| May 4, 2026 8:36 am | Yasmeen Rahimi | Piper Sandler | $54.00 | $22.38 | TheFly | First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler |
| April 28, 2026 10:09 am | Emily Bodnar | H.C. Wainwright | $30.00 | $18.10 | TheFly | First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright |
| April 24, 2026 11:31 am | David Risinger | Leerink Partners | $46.00 | $19.00 | TheFly | First Tracks Biotherapeutics initiated with an Outperform at Leerink |
| April 21, 2026 9:01 am | Michael Yee | UBS | $45.00 | $18.60 | TheFly | First Tracks Biotherapeutics initiated with a Buy at UBS |
Latest News for TRAX
Shares of First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in…
SAN DIEGO, Calif. , May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in…
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TRAX.
U.S. House Trading
No House trades found for TRAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.